Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.
about
Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settingsVirologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South AfricaHIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backboneHigh-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimenEvaluation of a cost effective in-house method for HIV-1 drug resistance genotyping using plasma samplesDevelopment, validation and clinical evaluation of a low cost in-house HIV-1 drug resistance genotyping assay for Indian patientsHigh prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South AfricaPerformance of an in-house human immunodeficiency virus type 1 genotyping system for assessment of drug resistance in CubaStability of HIV-1 Nucleic Acids in Dried Blood Spot Samples for HIV-1 Drug Resistance GenotypingSingle genome amplification of proviral HIV-1 DNA from dried blood spot specimens collected during early infant screening programs in Lusaka, ZambiaDrug susceptibility and resistance mutations after first-line failure in resource limited settingsTransmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity.Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, ZambiaLong-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008-2010.Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapySharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillanceA pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only.No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South AfricaImplementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon.An in-house HIV genotyping assay for the detection of drug resistance mutations in Southeast Asian patients infected with HIV-1.Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.
P2860
Q28478154-5289F088-B54B-491E-AF17-6F58238471EDQ28481468-10CB9207-7779-45A7-9C9B-A720A0F6BAD7Q28482189-2482CE37-CB98-4CCB-91DC-D88B08AAFCAFQ28538692-F4A6F588-BC41-4CE4-A786-D719EDF2ACE1Q28539725-F0D3535B-9216-4D08-AC69-357237EE9F33Q28542561-64E52CA9-73FA-406A-9211-8E42BBC2DD13Q28543358-56FCED03-52F5-4D02-ADD9-615DEB4DB138Q28543384-63FE4D11-97C7-4594-B7BB-5BB9D8F020B4Q28546274-9A645479-23A3-4428-BBA7-6D68702803DBQ33625191-1A53CD32-3D90-4E4F-8947-EEA0B7B3D6C7Q34106181-400BF087-91F5-45A4-93CF-E79846DD52C0Q34606742-B6463EFE-9167-45C2-9B71-DC0FFFBC8E1EQ34997577-2429AD52-76CA-4FD5-AFA0-04DC0AE9D64FQ35066913-85C3C2EB-97BB-40F6-AD78-2EBB303DB173Q35810923-15B78A21-2FC1-4A3D-B0D0-9151AA4052FEQ35868716-BFC7FB7E-201D-49AD-8EEC-85801F9CEE3CQ36049082-66AFD3EC-3362-4C0A-BEC2-4F96D01C7F46Q36693481-B8EF87B7-D642-4DBA-9740-17454D77528AQ36794795-5A95B9E2-BBA9-450B-BD45-61866A19CB23Q37026509-960C948D-B6EC-4D20-9E78-F9304D879688Q37146865-E72B4D66-FE68-4E8D-AED8-B2F00E15AE65Q37613017-829A94A1-8880-46DE-B5A4-61D887467A2EQ37634044-484CF2BD-D94E-4FFE-BFD6-03EF2803CED7Q38853866-775DB000-36D2-4549-B469-539FFB80ACBCQ38854117-90355456-3662-4335-85CD-CE6EDED9DF32Q40623733-D77FFE63-28F8-46E2-85E2-AC752AB431CCQ45367650-0475B992-B32F-4646-9935-2163B46B5AFCQ50975515-021F958D-8DA5-4BE9-8AC5-8119220A0CCFQ52642470-8F36020D-E307-4298-9852-8D63F32583FB
P2860
Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Affordable in-house antiretrov ...... rmance in non-subtype B HIV-1.
@ast
Affordable in-house antiretrov ...... rmance in non-subtype B HIV-1.
@en
Affordable in-house antiretrov ...... rmance in non-subtype B HIV-1.
@nl
type
label
Affordable in-house antiretrov ...... rmance in non-subtype B HIV-1.
@ast
Affordable in-house antiretrov ...... rmance in non-subtype B HIV-1.
@en
Affordable in-house antiretrov ...... rmance in non-subtype B HIV-1.
@nl
prefLabel
Affordable in-house antiretrov ...... rmance in non-subtype B HIV-1.
@ast
Affordable in-house antiretrov ...... rmance in non-subtype B HIV-1.
@en
Affordable in-house antiretrov ...... rmance in non-subtype B HIV-1.
@nl
P2093
P2860
P50
P1476
Affordable in-house antiretrov ...... rmance in non-subtype B HIV-1.
@en
P2093
Carole L Wallis
Gwynn Stevens
Maria A Papathanasopoulos
Shabir Lakhi
Tobias F Rinke de Wit
Wendy Stevens
P2860
P304
P356
10.1016/J.JVIROMET.2009.11.011
P577
2009-11-14T00:00:00Z